This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guadagni, F. Articles by Schlom, J. Search for Related Content PubMed PubMed Citation Articles by Guadagni, F. Articles by Schlom, J.

Detection of Blood-borne Cells in Colorectal Cancer Patients by Nested Reverse Transcription-Polymerase Chain Reaction for Carcinoembryonic Antigen Messenger RNA

Longitudinal Analyses and Demonstration of Its Potential Importance as an Adjunct to Multiple Serum Markers¹

Laboratory of Clinical Pathology [F. G., S. A., M. D. C., A. S., R. D. A., M. R. A.], II Division of Surgical Oncology [M. C., F. G., F. C.], III Division of Surgical Oncology [S. C., P. P.], and Department of Pathology [F. S.], Regina Elena Cancer Institute, 00144 Rome, Italy; Laboratory of Tumor Immunology and Biology [J. K., J. W. G., S. V. S. K., J. S.], Biostatistics and Data Management Section [S. M. S.], National Cancer Institute, NIH, Bethesda, Maryland 20892; and Department of Surgery, University of Rome Tor Vergata, 00144 Rome, Italy [M. R.]

The use of reverse transcription-PCR (RT-PCR) to analyze cells in the blood of cancer patients for the detection of mRNA expressed in tumor cells has implications for both the prognosis and the monitoring of cancer patients for the efficacy of established or experimental therapies. Carcinoembryonic antigen (CEA) is expressed on 95% of colorectal, gastric, and pancreatic tumors, and on the majority of breast, non-small cell lung, and head and neck carcinomas. CEA shed in serum is useful as a marker in only 50% of colorectal cancer patients and rarely is shed by some other carcinoma types. RT-PCR has been used previously to detect CEA mRNA in cells in the blood and lymph nodes of cancer patients. Under the assay conditions validated in the studies reported here, 34 of 51 (67%) patients with different stages of colorectal cancer had blood cells that were positive by RT-PCR for CEA mRNA, whereas none of 18 patients with colonic polyps were positive; 2 of 60 apparently healthy individuals (who were age and sex matched with the carcinoma patients and were part of a colon cancer screening program as controls) were marginally positive. The results of CEA PCR in the blood of the carcinoma patients and the other groups showed strong statistical correlation with the disease (P2 < 0.0001). Analyses were carried out to detect both serum CEA protein levels and CEA mRNA in blood cells of colorectal carcinoma patients by RT-PCR. For all stages of disease, 18 of 51 patients (35%) were positive for serum CEA, whereas 35 of 51 (69%) were positive by RT-PCR. More importantly, only 5 of 23 (20%) of stage B and C colorectal cancer patients were positive for serum CEA, whereas 16 of 23 (70%) were positive by RT-PCR. The use of two other serum markers (CA19.9 and CA72-4) for colorectal cancer in combination with serum CEA scored two additional patients as positive; both were positive by RT-PCR for CEA mRNA. Pilot long-term longitudinal studies conducted before and after surgery identified some patients with CEA mRNA in blood cells that were negative for all serum markers, who eventually developed clinical metastatic disease. The studies reported here are the first to correlate RT-PCR results for CEA mRNA in blood cells with one or more serum markers for patients with different stages of colorectal cancer, and are the first long-term longitudinal studies to use RT-PCR to detect CEA mRNA in blood cells of cancer patients. Larger cohorts will be required in future studies to define the impact, if any, of this technology on prognosis and/or disease monitoring.

This article has been cited by other articles:

				H. Katsuno, E. Zacharakis, O. Aziz, C. Rao, S. Deeba, P. Paraskeva, P. Ziprin, T. Athanasiou, and A. Darzi Does the Presence of Circulating Tumor Cells in the Venous Drainage of Curative Colorectal Cancer Resections Determine Prognosis? A Meta-Analysis Ann. Surg. Oncol., November 1, 2008; 15(11): 3083 - 3091. [Abstract] [Full Text] [PDF]

				S. Hundt, U. Haug, and H. Brenner Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1935 - 1953. [Abstract] [Full Text] [PDF]

				J.-Y. Wang, S.-R. Lin, D.-C. Wu, C.-Y. Lu, F.-J. Yu, J.-S. Hsieh, T.-L. Cheng, L.-B. Koay, and Y.-H. Uen Multiple Molecular Markers as Predictors of Colorectal Cancer in Patients with Normal Perioperative Serum Carcinoembryonic Antigen Levels Clin. Cancer Res., April 15, 2007; 13(8): 2406 - 2413. [Abstract] [Full Text] [PDF]

				T. Setoyama, S. Natsugoe, H. Okumura, M. Matsumoto, Y. Uchikado, S. Ishigami, T. Owaki, S. Takao, and T. Aikou Carcinoembryonic antigen messenger RNA expression in blood predicts recurrence in esophageal cancer. Clin. Cancer Res., October 15, 2006; 12(20): 5972 - 5977. [Abstract] [Full Text] [PDF]

				S. Sadahiro, T. Suzuki, K. Ishikawa, T. Saguchi, Y. Maeda, S. Yasuda, H. Makuuchi, S. Yurimoto, and C. Murayama Detection of Carcinoembryonic Antigen Messenger RNA-Expressing Cells in Portal and Peripheral Blood During Surgery Does Not Influence Relapse in Colorectal Cancer Ann. Surg. Oncol., December 1, 2005; 12(12): 988 - 994. [Abstract] [Full Text] [PDF]

				Y. Mataki, S. Takao, K. Maemura, S. Mori, H. Shinchi, S. Natsugoe, and T. Aikou Carcinoembryonic Antigen Messenger RNA Expression Using Nested Reverse Transcription-PCR in the Peripheral Blood During Follow-up Period of Patients Who Underwent Curative Surgery for Biliary-Pancreatic Cancer: Longitudinal Analyses Clin. Cancer Res., June 1, 2004; 10(11): 3807 - 3814. [Abstract] [Full Text] [PDF]

				G. F. V. Woude, G. J. Kelloff, R. W. Ruddon, H.-M. Koo, C. C. Sigman, J. C. Barrett, R. W. Day, A. P. Dicker, R. S. Kerbel, D. R. Parkinson, et al. Reanalysis of Cancer Drugs: Old Drugs, New Tricks Clin. Cancer Res., June 1, 2004; 10(11): 3897 - 3907. [Full Text] [PDF]

				Y. Li, Y. Chen, J. Dilley, T. Arroyo, D. Ko, P. Working, and D.-C. Yu Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy Mol. Cancer Ther., October 1, 2003; 2(10): 1003 - 1009. [Abstract] [Full Text]

				N. Waguri, T. Suda, M. Nomoto, H. Kawai, Y. Mita, T. Kuroiwa, M. Igarashi, M. Kobayashi, Y. Fukuhara, and Y. Aoyagi Sensitive and Specific Detection of Circulating Cancer Cells in Patients with Hepatocellular Carcinoma; Detection of Human Telomerase Reverse Transcriptase Messenger RNA after Immunomagnetic Separation Clin. Cancer Res., August 1, 2003; 9(8): 3004 - 3011. [Abstract] [Full Text] [PDF]

				E. S. Kass, J. W. Greiner, J. A. Kantor, K. Y. Tsang, F. Guadagni, Z. Chen, B. Clark, R. D. Pascalis, J. Schlom, and C. Van Waes Carcinoembryonic Antigen as a Target for Specific Antitumor Immunotherapy of Head and Neck Cancer Cancer Res., September 1, 2002; 62(17): 5049 - 5057. [Abstract] [Full Text] [PDF]